Cite
Yamada M, Miller DM, Lowe M, et al. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemp Clin Trials Commun. 2021;23:100830doi: 10.1016/j.conctc.2021.100830.
Yamada, M., Miller, D. M., Lowe, M., Rowe, C., Wood, D., Soyer, H. P., Byrnes-Blake, K., Parrish-Novak, J., Ishak, L., Olson, J. M., Brandt, G., Griffin, P., Spelman, L., & Prow, T. W. (2021). A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary clinical trials communications, 23100830. https://doi.org/10.1016/j.conctc.2021.100830
Yamada, Miko, et al. "A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients." Contemporary clinical trials communications vol. 23 (2021): 100830. doi: https://doi.org/10.1016/j.conctc.2021.100830
Yamada M, Miller DM, Lowe M, Rowe C, Wood D, Soyer HP, Byrnes-Blake K, Parrish-Novak J, Ishak L, Olson JM, Brandt G, Griffin P, Spelman L, Prow TW. A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemp Clin Trials Commun. 2021 Aug 04;23:100830. doi: 10.1016/j.conctc.2021.100830. eCollection 2021 Sep. PMID: 34401600; PMCID: PMC8355837.
Copy
Download .nbib